Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia
CREEK
CREEK is a Multicenter Retrospective Study to Understand the Clinical Characteristics, Treatment Pathway and Resource Utilization for Patients With Chronic Lymphocytic Leukemia in International Region.
1 other identifier
observational
1,088
16 countries
49
Brief Summary
A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2021
49 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 8, 2021
CompletedFirst Posted
Study publicly available on registry
July 16, 2021
CompletedStudy Start
First participant enrolled
December 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2023
CompletedFebruary 20, 2024
February 1, 2024
1.7 years
July 8, 2021
February 16, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients, recording the patient characteristic: \- Demographics: (Age, gender, race, nationality, Performance status, Tobacco use, Family history of malignancies)
5 year
Calculation of Epidemiological Measure(s) of Interest
Calculation of Epidemiological Measure(s) of Interest e.g., descriptive statistics, hazard ratios, incidence rates, test/retest reliability)
5 years
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients, recording the patient characteristic: * Laboratory Status: * CBC: Hemoglobin, Total leucocytic count, neutrophils, lymphocytes, and platelets * Renal functions: serum creatinine, Urea, eGFR * Hepatic function: ALT and AST * Concomitant medications: * Antagonists of vitamin K * Oral Anticoagulants: rivaroxaban, apixaban, dabigatran * Proton pump inhibitors (PPIs) * H2 Antagonists * Antacids * Others
5 Years
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients
To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients, recording the patient characteristic: * Comorbidities. * Risk stratification
5 Years
To describe disease Characteristics
To describe Staging of disease, Prognosis, Cytogenetics abnormalities and Immunogenetic analysis * Date of diagnosis * Staging of disease
5 Years
To describe disease Characteristics
To describe Staging of disease, Prognosis, Cytogenetics abnormalities and Immunogenetic analysis * Prognosis made by fluorescence in situ hybridization (FISH) * Immunogenetic analysis
5 Years
Secondary Outcomes (3)
Recording the treatment patterns
5 years
Calculation of Epidemiological Measure(s) of Interest
5 Years
Subsequent lines of therapies
5 Years
Other Outcomes (1)
Recording the treatment-related outcomes
5 years
Eligibility Criteria
with chronic lymphocytic leukemia (CLL) subjects diagnosed
You may qualify if:
- Primary diagnosis of Chronic Lymphocytic Leukemia (CLL)
- Initiated CLL treatment (including 1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016, and 12 months before data collection
- \- For GCC pilot cohort patients: treatment-naive CLL patients diagnosed between 01 June 2016, and 12 months before data collection.
- Available medical records at the participating site reflecting at least 12 months of follow-up after starting on treatment (except in the case of the participant death within one year following treatment initiation).
- Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations.
- Adult male or female ≥18 years old at the time of diagnosis or according to the age of majority as defined by local regulations).
You may not qualify if:
- Any diagnosis of B-cell malignancies other than CLL.
- Current or prior use of "acalabrutinib" treatment.
- Currently/previously receiving treatment in an interventional clinical trial at the time of entry into this study for indications CLL.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (52)
Research Site
Buenos Aires, C1114, Argentina
Research Site
Buenos Aires, C1115, Argentina
Research Site
Campinas, 13083-887, Brazil
Research Site
Jaú, 17210-080, Brazil
Research Site
São Paulo, 01236-030, Brazil
Research Site
São Paulo, 04502-001, Brazil
Research Site
São Paulo, 1409, Brazil
Research Site
Providencia, 7500000, Chile
Research Site
Bogotá, 110111, Colombia
Research Site
Cali, 760045, Colombia
Research Site
Medellín, 050010, Colombia
Research Site
San José, 10203, Costa Rica
Research Site
Santo Domingo. D.N., Dominican Republic, 10103, Dominican Republic
Research Site
Alexandria, 11591, Egypt
Research Site
Cairo, 11566, Egypt
Research Site
Cairo, 11591, Egypt
Research Site
Cairo, 11796, Egypt
Research Site
Cairo, 12611, Egypt
Research Site
Luxor, 85863, Egypt
Research Site
Manipal, India, 560017, India
Research Site
Ahmedabad, 380009, India
Research Site
Delhi, 110005, India
Research Site
Delhi, 110017, India
Research Site
Faridabad, 121001, India
Research Site
Haryāna, 122002, India
Research Site
Hyderabad, 500082, India
Research Site
Kashmīr, 190011, India
Research Site
Kolkata, 711103, India
Research Site
Mumbai, 400012, India
Research Site
Kuwait City, 42262, Kuwait
Research Site
Kuala Selangor, Malaysia, 47500, Malaysia
Research Site
Kuala Selangor, Malaysia, 68000, Malaysia
Research Site
Johor Bahru, 80100, Malaysia
Research Site
Kuala Lumpur, 59100, Malaysia
Research Site
Mexico City, 06726, Mexico
Research Site
Monterrey, 64460, Mexico
Research Site
Panama City, Panama 4, Panama
Research Site
Jeddah, 21423, Saudi Arabia
Research Site
Riyadh, 11426, Saudi Arabia
Research Site
Riyadh, 12231, Saudi Arabia
Research Site
Singapore, 119228, Singapore
Research Site
Singapore, 168582, Singapore
Research Site
Singapore, 308433, Singapore
Research Site
Taichung, 407219, Taiwan
Research Site
Taipei, 100225, Taiwan
Research Site
Adana/Saricam, Turkey, 1330, Turkey (Türkiye)
Research Site
Izmir/ Bornova, Turkey, 35100, Turkey (Türkiye)
Research Site
Izmir/Balcova, Turkey, 35330, Turkey (Türkiye)
Research Site
Samsun/Atakum, Turkey, 55280, Turkey (Türkiye)
Research Site
Ankara/Altindag, 6230, Turkey (Türkiye)
Research Site
Ankara/Yenimahalle, 6560, Turkey (Türkiye)
Research Site
Abu Dhabi, 11001, United Arab Emirates
Related Publications (1)
Abdelmoaty M, Alshehri H, Alamoudi S, Buyukasik Y, Abdelfattah R, Alorabi M, Kamal A, Aboutaleb A, Alhejazi A. Chronic lymphocytic leukaemia in the Middle East: a subgroup analysis from the CREEK study on treatment patterns and outcomes. Expert Rev Anticancer Ther. 2025 Nov 11:1-12. doi: 10.1080/14737140.2025.2582649. Online ahead of print.
PMID: 41175395DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 8, 2021
First Posted
July 16, 2021
Study Start
December 3, 2021
Primary Completion
August 31, 2023
Study Completion
August 31, 2023
Last Updated
February 20, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Url Preview for AstraZeneca Clinical Trials Website AstraZeneca Clinical Trials Website This web site provides clinical trial data, results and other information regarding clinical trials astrazenecagrouptrials.pharmacm.com
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.